Abstract Number: 1123 • 2019 ACR/ARP Annual Meeting
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Background/Purpose: Smoking doubles the risk of developing RA, and continuing to smoke after RA diagnosis is associated with worse disease control, treatment failure, and premature…Abstract Number: 1124 • 2019 ACR/ARP Annual Meeting
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE tends to peak during prime working years, resulting in a high economic burden due…Abstract Number: 1125 • 2019 ACR/ARP Annual Meeting
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective…Abstract Number: 1126 • 2019 ACR/ARP Annual Meeting
A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing osteoporosis as compared to the general population, even after controlling for glucocorticoid use[1]. Identification…Abstract Number: 1127 • 2019 ACR/ARP Annual Meeting
Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology
Background/Purpose: The transition from pediatric to adult care is a vulnerable period, in which poor health outcomes are reported amongst youth transferring to adult care.…Abstract Number: 1128 • 2019 ACR/ARP Annual Meeting
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis…Abstract Number: 1129 • 2019 ACR/ARP Annual Meeting
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Background/Purpose: Symptomatic knee OA affects 14 million adults in the US. Recent estimates suggest that about 40% of people with knee OA are taking prescription…Abstract Number: 1130 • 2019 ACR/ARP Annual Meeting
The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Background/Purpose: Background: Hydroxychloroquine (HCQ) is widely used in treatment of autoimmune rhuematological diseases. In particular, systemic lupus erythermatosus where it proved to prevent disease flare, reduce…Abstract Number: 1131 • 2019 ACR/ARP Annual Meeting
Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?
Background/Purpose: The information associated with loss to follow-up (LFU) patients may affect real-world data evaluation of the use of biologics that is not being adequately…Abstract Number: 1132 • 2019 ACR/ARP Annual Meeting
Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Background/Purpose: Biologic disease modifying agents (DMARDs) are an integral part of rheumatoid arthritis (RA) treatment, but the adoption of infusion-based products has not been reported.…Abstract Number: 1133 • 2019 ACR/ARP Annual Meeting
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Background/Purpose: Biologic disease modifying agents (DMARDs) have become an integral part of rheumatoid arthritis (RA) treatment guidelines, but they are associated with a substantial increase…Abstract Number: 1134 • 2019 ACR/ARP Annual Meeting
Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Background/Purpose: The management of rheumatoid arthritis (RA) and other conditions have improved tremendously since the introduction of biologic disease modifying agents (DMARDs). However, these agents…Abstract Number: 1135 • 2019 ACR/ARP Annual Meeting
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Background/Purpose: Flares in rheumatoid arthritis (RA) are common. The shortage of readily available specialized care may hinder early detection and timely management of RA flares.…Abstract Number: 1136 • 2019 ACR/ARP Annual Meeting
Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
Background/Purpose: No shows are a widespread problem across medical practices, and lead to negative consequences for patients and providers (Mendel 2017). The rheumatology division at…Abstract Number: 1137 • 2019 ACR/ARP Annual Meeting
Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database
Background/Purpose: Musculoskeletal diseases (MSKs) are the major cause of disability, affecting the patient's daily activities as well as their Quality of Life (QoL). Our objective…
ACR Meeting Abstracts